These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 20460482)
21. Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Bachireddy P; Hainz U; Rooney M; Pozdnyakova O; Aldridge J; Zhang W; Liao X; Hodi FS; O'Connell K; Haining WN; Goldstein NR; Canning CM; Soiffer RJ; Ritz J; Hacohen N; Alyea EP; Kim HT; Wu CJ Blood; 2014 Feb; 123(9):1412-21. PubMed ID: 24357730 [TBL] [Abstract][Full Text] [Related]
22. Identification of T-cell clones showing expansion associated with graft-vs-leukemia effect on chronic myelogenous leukemia in vivo and in vitro. Kondo Y; Shiobara S; Nakao S Exp Hematol; 2001 Apr; 29(4):471-6. PubMed ID: 11301187 [TBL] [Abstract][Full Text] [Related]
23. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. Bilich T; Nelde A; Bichmann L; Roerden M; Salih HR; Kowalewski DJ; Schuster H; Tsou CC; Marcu A; Neidert MC; Lübke M; Rieth J; Schemionek M; Brümmendorf TH; Vucinic V; Niederwieser D; Bauer J; Märklin M; Peper JK; Klein R; Kohlbacher O; Kanz L; Rammensee HG; Stevanović S; Walz JS Blood; 2019 Feb; 133(6):550-565. PubMed ID: 30530751 [TBL] [Abstract][Full Text] [Related]
24. Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. Bornhäuser M; Thiede C; Platzbecker U; Kiani A; Oelschlaegel U; Babatz J; Lehmann D; Hölig K; Radke J; Tuve S; Wermke M; Wehner R; Jähnisch H; Bachmann MP; Rieber EP; Schetelig J; Ehninger G; Schmitz M Blood; 2011 Jun; 117(26):7174-84. PubMed ID: 21540460 [TBL] [Abstract][Full Text] [Related]
25. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion. Schattenberg A; Schaap N; Van De Wiel-Van Kemenade E; Bär B; Preijers F; Van Der Maazen R; Roovers E; De Witte T Leuk Lymphoma; 1999 Jan; 32(3-4):317-25. PubMed ID: 10037029 [TBL] [Abstract][Full Text] [Related]
26. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Faber LM; van Luxemburg-Heijs SA; Veenhof WF; Willemze R; Falkenburg JH Blood; 1995 Oct; 86(7):2821-8. PubMed ID: 7670118 [TBL] [Abstract][Full Text] [Related]
27. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity. Stumpf AN; van der Meijden ED; van Bergen CA; Willemze R; Falkenburg JH; Griffioen M Blood; 2009 Oct; 114(17):3684-92. PubMed ID: 19706888 [TBL] [Abstract][Full Text] [Related]
28. Identification of novel minor histocompatibility antigens responsible for graft-versus-leukemia (GVL) effect on chronic myeloid leukemia: usefulness of determining the clonotype of T cells associated with GVL effect after donor leukocyte infusion. Nakao S Int J Hematol; 2002 Aug; 76 Suppl 1():274-6. PubMed ID: 12430863 [TBL] [Abstract][Full Text] [Related]
29. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Dazzi F; Szydlo RM; Cross NC; Craddock C; Kaeda J; Kanfer E; Cwynarski K; Olavarria E; Yong A; Apperley JF; Goldman JM Blood; 2000 Oct; 96(8):2712-6. PubMed ID: 11023502 [TBL] [Abstract][Full Text] [Related]
30. HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion. Stevanovic S; van Bergen CA; van Luxemburg-Heijs SA; van der Zouwen B; Jordanova ES; Kruisselbrink AB; van de Meent M; Harskamp JC; Claas FH; Marijt EW; Zwaginga JJ; Halkes CJ; Jedema I; Griffioen M; Falkenburg JH Blood; 2013 Sep; 122(11):1963-73. PubMed ID: 23777765 [TBL] [Abstract][Full Text] [Related]
31. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen. Rodolfo M; Luksch R; Stockert E; Chen YT; Collini P; Ranzani T; Lombardo C; Dalerba P; Rivoltini L; Arienti F; Fossati-Bellani F; Old LJ; Parmiani G; Castelli C Cancer Res; 2003 Oct; 63(20):6948-55. PubMed ID: 14583496 [TBL] [Abstract][Full Text] [Related]
33. CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II. van Balen P; van Bergen CAM; van Luxemburg-Heijs SAP; de Klerk W; van Egmond EHM; Veld SAJ; Halkes CJM; Zwaginga JJ; Griffioen M; Jedema I; Falkenburg JHF Front Immunol; 2018; 9():3016. PubMed ID: 30619360 [TBL] [Abstract][Full Text] [Related]
34. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation. Chiorean EG; DeFor TE; Weisdorf DJ; Blazar BR; McGlave PB; Burns LJ; Brown C; Miller JS Biol Blood Marrow Transplant; 2004 Mar; 10(3):171-7. PubMed ID: 14993882 [TBL] [Abstract][Full Text] [Related]
35. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. Sehn LH; Alyea EP; Weller E; Canning C; Lee S; Ritz J; Antin JH; Soiffer RJ J Clin Oncol; 1999 Feb; 17(2):561-8. PubMed ID: 10080600 [TBL] [Abstract][Full Text] [Related]
36. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886 [TBL] [Abstract][Full Text] [Related]
37. Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans. Lin Y; Zhang L; Cai AX; Lee M; Zhang W; Neuberg D; Canning CM; Soiffer RJ; Alyea EP; Ritz J; Hacohen N; Means TK; Wu CJ J Clin Invest; 2011 Apr; 121(4):1574-84. PubMed ID: 21403403 [TBL] [Abstract][Full Text] [Related]
38. Ex vivo-expanded donor CD4(+) lymphocyte infusion against relapsing neuroblastoma: A transient graft-versus-tumor effect. Yoshida H; Kusuki S; Hashii Y; Ohta H; Morio T; Ozono K Pediatr Blood Cancer; 2009 Jul; 52(7):895-7. PubMed ID: 19191346 [TBL] [Abstract][Full Text] [Related]
39. Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: a therapeutic strategy. Novitzky N; Rubinstein R; Hallett JM; du Toit CE; Thomas VL Transplantation; 2000 Apr; 69(7):1358-63. PubMed ID: 10798754 [TBL] [Abstract][Full Text] [Related]
40. Graft-versus-leukemia effect in minor antigen mismatched chimeras given delayed donor leucocyte infusion: immunoregulatory aspects and role of donor T and ASGM1-positive cells. Sefrioui H; Billiau AD; Waer M Transplantation; 2000 Jul; 70(2):348-53. PubMed ID: 10933162 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]